89bio announces appointment of teresa perney, ph.d. as chief regulatory and quality officer

San francisco, sept. 16, 2024 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of teresa perney, ph.d. as chief regulatory and quality officer, effective today. dr. perney brings an extensive track record of expertise and leadership in regulatory, product development and quality in the industry to the company.
ETNB Ratings Summary
ETNB Quant Ranking